Tag Archives: ADC

January, 2018

18 January
Daiichi-Sankyo Presents Updated Data for DS-8201 in Patients with HER2-Expressing Gastric Cancer

TOKYO, BASKING RIDGE, N.J. and MUNICH, Jan. 18, 2018 /PRNewswire/ — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that updated phase 1 safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate (ADC), in a subgroup of patients with HER2-expressing gastric cancer previously treated with trastuzumab …
Share

3 November
Seattle Genetics Submits sBLA to FDA for Adcetris in Frontline Advanced Hodgkin Lymphoma

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-1 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced …
Share

11 October
Seattle Genetics Enters Two New Collaborations to Evaluating SGN-LIV1A in Triple Negative Breast Cancer

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ: SGEN) today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer (TNBC). SGN-LIV1A is an investigational antibody-drug conjugate (ADC) that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, …
Share

22 September
AbbVie Announces Another Combination Trial Evaluating New ADC with Bristol-Myers Squibb’s Opdivo

NORTH CHICAGO, Ill. & NEW YORK–(BUSINESS WIRE)–AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie’s investigational antibody drug conjugate ABBV-399 and Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer (NSCLC). A Phase 1b clinical study is underway that includes …
Share
8 September
Seattle Genetics Presents Promising Data with Tisotumab Vedotin in Cervical Cancer

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that preliminary clinical data for tisotumab vedotin from a Genmab-sponsored phase 1/2 clinical trial (GEN701) are being featured in an oral presentation at the European Society for Medical Oncology (ESMO) Congress being held September 8-12, 2017 in Madrid, Spain. Additional data from …
Share

29 June
Seattle Genetics and Takeda Announce Positive Results from Late-Stage NHL Trial

CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash.–(BUSINESS WIRE)–Jun. 26, 2017– Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (PFS) versus the control arm. ECHELON-1 is …
Share

31 May
ImmunoGen and Sanofi Amend License Agreements Covering All Sanofi Compounds Using ImmunoGen’s Technology

WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company and an affiliate of Sanofi have amended their license agreements covering all compounds in development by Sanofi using ImmunoGen’s technology. Under the terms of …
Share

5 April
Immunomedics’ Lead ADC is Active in Patients with Metastatic Small-Cell Lung Cancer

Washington, D.C., April 5, 2017 — Immunomedics, Inc., (NASDAQ: IMMU) (“Immunomedics” or “the Company”) today reported that sacituzumab govitecan (IMMU-132), the Company’s lead antibody-drug conjugate (ADC), has activity and manageable toxicity in patients with advanced and heavily-pretreated metastatic small-cell lung cancer (SCLC). “Despite recent progress in immunotherapy and the identification …
Share

10 February
Immunomedics in up to $2 Billion License Agreement with Seattle Genetics for Sacituzumab Govitecan

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: IMMU) under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, …
Share

13 July
Celldex Initiates Phase 1/2 Clinical Trial of New Product Candidate in Advanced RCC

HAMPTON, N.J., July 11, 2016 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened in its Phase 1/2 study of CDX-014 in advanced renal cell carcinoma (RCC). CDX-014 is a novel antibody-drug conjugate that targets the transmembrane protein T-cell immunoglobulin mucin-1 (TIM-1). TIM-1 expression is upregulated …
Share

Page 1 of 212 »